Publications by authors named "B Visseaux"
Article Synopsis
- Serological data collected in France from 2018 to 2022 revealed seroprevalence rates for various viruses: HSV-1 (64.6%), HSV-2 (16.9%), VZV (93.0%), EBV (83.4%), and CMV (49.0%).* -
- The study utilized a multilevel regression and poststratification approach to ensure accurate estimates across different demographics and regions.* -
- Findings indicate that expected seroprevalence rates were generally higher among females and in overseas territories compared to Metropolitan France, suggesting the need for tailored public health strategies.*
Article Synopsis
- - From April 2023 to May 2024, France saw a significant increase in parvovirus B19 (B19V) infections, with IgM-positive cases four times higher than in the 2019 epidemic.
- - Clinical data supported the rise, showing adverse health effects, especially in children, while adults mostly showed increased lab-confirmed cases.
- - It's crucial for physicians and policymakers to be alerted so they can improve prevention, diagnosis, and management for vulnerable patients.
Unlabelled: The susceptibility of genetically divergent HIV-1 strains (HIV-1 non-M) from groups O, N, and P to the CCR5 co-receptor antagonist, maraviroc (MVC), was investigated among a large panel of 45 clinical strains, representative of the viral genetic diversity. The results were compared to the reference strains of HIV-1 group M (HIV-1/M) with known tropism. Among the non-M strains, a wide range of phenotypic susceptibilities to MVC were observed.
View Article and Find Full Text PDFIntroduction: This study evaluated the clinical and analytical performances of the Access HBsAg and the Access HBsAg Confirmatory assays on the DxI 9000 Access Immunoassay Analyzer (Beckman Coulter, Inc.).
Materials And Methods: Diagnostic specificity and sensitivity of the Access HBsAg and Access HBsAg Confirmatory assays were evaluated by comparing the Access assays to the final HBsAg sample status determined using the Architect, PRISM, or Elecsys HBsAg assays, along with Architect or PRISM HBsAg Confirmatory assays.
Article Synopsis
- * Deceased patients had significantly higher positivity rates and median N-antigenemia levels compared to survivors, suggesting a correlation between elevated N-antigenemia and worse outcomes.
- * The findings indicate that deceased patients take longer to clear N-antigen from their blood; however, the viral load in nasopharyngeal swabs did not show a significant difference between deceased and surviving patients.